Navigation Links
Cancer Care Compromised by Cost

A team of researchers has recommended that, in order to implement better cancer care to patients certain reforms have to be mustered immediately. //Their views were published in the British Medical journal. The team of researchers opined that the National Institute for Health and Clinical Excellence (NICE) should amend some of their modes of action, in order to cater to the immediate needs of cancer patients. More planning is essential to ensure that those battling with cancer shall be assured supply of life saving drugs through the NHS.

Last August NICE, had pointed that unless local Trusts mobilized funds, they would be unable to cover the entire costs of drugs like Herceptin to patients. Herceptin is a drug that can fight cancer by targeting a protein, the HER2 protein, which can trigger off tumors. Almost 20% of breast cancers are noted to be HER2 positive. NICE has ruled that, all breast cancer patients that are HER2 would benefit from treatment with Herpecitin following chemotherapy, surgery or radiation therapy. However following this ruling, no move has been made by NICE to indicate where the extra funds should be recovered from. Unless federal funds are released, cancer patient who cannot afford the treatment cannot get the benefits.

Doctors from Norwich University Hospital NHS Trust studied the data linked to the bulk of cancer patients receiving treatment at their hospital. Their findings show that 1.9 million pounds are required to make the drug Herpecitin available to all patients who need the drug. Costs cannot be contained with the treatment alone. The projected expense can be covered only if the equally important palliative care or chemotherapy is done away with, they concluded.

There is no conclusive data that shows that there are any long term benefits that the drug Herpecetin, promises except that it is the drug of choice at this moment. That is not a reliable reason to deny patients conventional treatment and sw itch over to Herpecitin, which is not cost effective either, say doctors.

Doctors who were part of the study opine that, in an ideal situation the government should back up their decision by providing the source of funding for newer drugs. Suggestions have been framed, urging the Department of Health to keep aside money to fund NICE.
MST
'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
Breaking Medicine Technology: